Zeformin XR 60 Tablet is a combination oral antidiabetic medication containing Gliclazide 60 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity. The extended-release formulation of Zeformin XR facilitates a gradual release of active ingredients, promoting sustained blood glucose regulation and improving patient compliance through once-daily dosing. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. Zeformin XR 60 should be used as part of a comprehensive diabetes management plan, including diet modification and regular physical activity. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Regular monitoring of blood glucose levels and renal function is recommended to ensure safety and efficacy. Zeformin XR 60 Tablet offers an effective therapeutic option for improved glycemic control in type 2 diabetes patients.